Business Wire

QuantrolOx Unveils VIDYAQAR — the World’s First True Open-Architecture Quantum Platform for Education, Research, Testing and Benchmarking

10.12.2025 13:29:00 CET | Business Wire | Press Release

Share

QuantrolOx today announced a major milestone in quantum technology with the launch of VIDYAQAR, the world’s first True Open-Architecture Quantum Platform designed specifically for education, research, testing, and benchmarking. The system was unveiled today in India and will be available globally in the first half of 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210668898/en/

VIDYAQAR - A complete quantum platform with cryogenics, control hardware and QPU - powered by Quantum EDGE.

The name VIDYAQAR derives from the Sanskrit Vidyākar, meaning “causing wisdom, giving knowledge or science”—a perfect reflection of the platform’s mission to widen access to advanced quantum hardware and accelerate innovation.

A Complete, Open and Scalable Quantum Platform

VIDYAQAR is a connected, fully open-architecture superconducting quantum system that brings together:

  • Cryogenics
  • Control electronics
  • Quantum Processing Unit (QPU)
  • Integrated Quantum EDGE software stack

Designed for organisations entering the quantum domain for the first time, VIDYAQAR enables teams to start running experiments on day one, customize every layer of the system without constraints, and scale their infrastructure over time.

This is True Open Architecture: transparent, flexible, and modular.

Why VIDYAQAR Matters

A thriving quantum ecosystem requires shared, open testbeds where hardware, software, and control methods can be prototyped, validated, and benchmarked. VIDYAQAR fills this critical gap.

The platform supports a national or institutional quantum strategy by enabling:

  • Rapid prototyping of new ideas in quantum hardware, software, and control
  • Collaboration between universities, government labs, and industry
  • Development of standards, interoperability frameworks, and indigenous capability
  • Deployment of a scalable national network of quantum systems

VIDYAQAR is built on QuantrolOx’s proven open-architecture quantum computer in Delft, already running with multiple QPUs, electronics stacks, and cryogenic components.

Built for Learning — and for Serious R&D

VIDYAQAR is not only a research powerhouse but also an ideal training environment for the next generation of quantum experts. Key features include:

  • Quantum EDGE Academy — A comprehensive training program for mastering superconducting quantum hardware
  • Python SDK — Full programmability for custom experiments, libraries, and workflows
  • Built-in automation with Quantum EDGE — Accelerates bring-up, characterization, calibration, and tuning
  • Modular scalability — Upgrade from a single system to a centrally orchestrated “system of systems”

Availability

VIDYAQAR launches today in India and will be available to customers worldwide in 1H 2026.

QuantrolOx invites universities, national research facilities, and industrial R&D labs seeking an open, extensible quantum platform to join us on the journey to quantum computing.

About QuantrolOx

QuantrolOx develops Quantum EDGE, a next-generation measurement and automation platform that supercharges quantum R&D. Quantum EDGE provides industry-leading capabilities in measurement and automation, all with a modern, polished user interface that is intuitive to use and designed to simplify the complexity of quantum hardware. It works out of the box and integrates with leading instruments. Quantum EDGE is developed and tested on real quantum setups with multiple QPUs across varying architectures - so you can trust it to work reliably in actual lab environments.

Instead of teams of PhD experts spending days manually tuning qubits, Quantum EDGE can automatically characterise and tune a 2-qubit gate in under 25 minutes, and repeat this reliably. That means thousands of development cycles per year instead of just a handful, so hardware teams can improve their qubits much faster. This rapid iteration is essential for building fault-tolerant quantum computers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251210668898/en/

Contacts

Media Contact
QuantrolOx
Vishal Chatrath
Chief Executive Officer, QuantrolOx
Email: vishal@quantrolox.com
www.quantrolox.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.quantrolox.
com&esheet=54373398&newsitemid=20251210668898&lan=en-US&anchor=www.quantrolox.co
m&index=1&md5=40cf67e2f7aeacd1c825d4cf9cfde12f

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye